Amgen maps a PhIII journey for its latest great cardio drug hopeful. Can it succeed this time?

Just a few days ago, Amgen CEO Bob Bradway touted one of the company’s cardio programs for a drug called olpasiran as one of the top drugs in the pipeline. And now Bradway’s pharma giant has taken the wraps off a detailed and updated outline of Phase II data as...

Click to view original post